or
forgot password

a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.


Phase 3
18 Years
N/A
Not Enrolling
Female
Breast Neoplasms

Thank you

Trial Information

a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Inclusion Criteria


Inclusion Criteria

1. Locally advanced or metastatic breast cancer

2. Bi-dimensionally measurable disease

Exclusion Criteria

1. Prior hormonal therapy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

3883

NCT ID:

NCT00034125

Start Date:

Completion Date:

Related Keywords:

  • Breast Neoplasms
  • cancer
  • metastatic breast cancer
  • hormonal therapy
  • Breast Neoplasms
  • Neoplasms

Name

Location
Miami, Florida  33176
Nashville, Tennessee  37203-1632
Metairie, Louisiana  70006
Boston, Massachusetts